{"id":231414,"date":"2025-07-02T07:28:10","date_gmt":"2025-07-02T07:28:10","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/231414\/"},"modified":"2025-07-02T07:28:10","modified_gmt":"2025-07-02T07:28:10","slug":"obesity-drug-wegovy-available-from-pharmacies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/231414\/","title":{"rendered":"Obesity drug Wegovy available from pharmacies"},"content":{"rendered":"<p class=\"break-words ligatures-off prose-article-body-r print:leading-7\">Unlike Ozempic, which was originally designed to treat type 2 diabetes, Wegovy was specifically developed to treat obesity. The drug contains the same active ingredient, semaglutide, which suppresses appetite. Rybelsus, a pill version of Ozempic, is also on the market for diabetes patients.<\/p>\n<p class=\"break-words ligatures-off prose-article-body-r print:leading-7\">At present, Wegovy is not yet reimbursed by the health insurance. Manufacturer Novo Nordisk has applied for it to be reimbursed, but a decision is not expected until early next year. If agreed, reimbursement will not be retroactive.<\/p>\n<p class=\"break-words ligatures-off prose-article-body-r print:leading-7\">In the case of Ozempic and Mounjaro, reimbursement only applies when the drug is prescribed for type 2 diabetes. The manufacturer of Mounjaro is filing an application to get the drug reimbursed also when it is used to treat obesity.<\/p>\n","protected":false},"excerpt":{"rendered":"Unlike Ozempic, which was originally designed to treat type 2 diabetes, Wegovy was specifically developed to treat obesity.&hellip;\n","protected":false},"author":2,"featured_media":231415,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,16,15],"class_list":{"0":"post-231414","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114782463880105069","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/231414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=231414"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/231414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/231415"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=231414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=231414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=231414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}